commentary than any pharmaceutical policy since the Medicare Modernization Act of 2003 established Part D. Most of that commentary has focused on which drugs were selected, what the negotiated prices represent, and how manufacturers are likely to respond. Less attention has been paid to an empirical question that MedPricer’s cross-dataset architecture is positioned to help answer: once negotiated prices take effect, what will actually happen to ASP, WAC, and the broader pricing ecosystem for the affected drugs and their therapeutic class competitors?
The Negotiated Price and the ASP Relationship
CMS’s negotiated ‘maximum fair prices’ under the IRA apply specifically to Medicare Part D and Part B covered uses. For Part B drugs, the maximum fair price is relevant to the ASP calculation, but the exact mechanism—how manufacturers report the maximum fair price in their ASP submissions, and how it interacts with the existing ASP-plus-6% reimbursement framework—involves methodological questions that CMS is still working through in its implementation guidance.
For Part D drugs, the maximum fair price replaces ASP as the relevant pricing benchmark for Medicare use. This creates a bifurcated pricing environment: a negotiated price for Medicare-covered use and a market-determined net price for commercial coverage. The spread between these two pricing regimes—and the manufacturer’s ability to maintain higher commercial pricing while accepting the negotiated Medicare price—is one of the most consequential empirical questions the IRA creates.
Spill-Over Effects Into Commercial Pricing
Economic theory predicts that mandatory price reductions in one payer segment will lead manufacturers to offset lost revenue through higher prices or reduced rebates in other segments. Whether this ‘cost-shifting’ hypothesis applies to IRA-negotiated drugs is an empirical question that WAC-ASP trend data can begin to answer as the program takes effect.
If manufacturers of IRA-negotiated drugs begin raising WAC or reducing rebates in the commercial market to offset Medicare revenue compression, the evidence should appear in widening WAC-to-commercial-ASP spreads for the affected drugs. MedPricer’s cross-dataset architecture provides the baseline measurement against which post-IRA price movements can be compared. Without that baseline, attributing WAC changes or ASP movements to IRA-specific dynamics rather than concurrent market factors would be analytically difficult.
Class Effects and Competitive Dynamics
When a leading drug in a therapeutic class faces price negotiation, its competitors face a strategic choice: price down to remain competitive with the newly constrained market leader, or maintain pricing while positioning on non-price dimensions. The WAC and ASP trajectories of class competitors following IRA negotiation of the leading drug will reveal which competitive strategy prevails.
This class-level analysis is precisely the kind of cross-drug, cross-time comparison that MedPricer’s normalized dataset enables. Individual drug WAC changes tell part of the story; therapeutic class patterns tell a more complete one. Analysts modeling the IRA’s competitive effects cannot rely on single-drug price data—they need the class context that only a comprehensive, normalized dataset provides.
What the First Year of Negotiated Prices Will Actually Show
The first negotiated prices under the IRA took effect for a limited set of drugs in 2026. The empirical signal from this initial cohort will be modest—the drug selection was limited, the negotiated prices varied substantially in their depth of discount, and the affected drugs’ commercial market shares differ significantly. But the methodological precedent matters: this is the first time Medicare has a mechanism to set prices that will appear in benchmark data in a way that allows before-after comparison.
MedPricer’s value in this analytical exercise is not prediction—no external dataset can predict what a negotiated price will be before CMS announces it. The value is in systematic measurement after the fact: how did the affected drugs’ WAC-ASP spreads change, how did class competitor pricing respond, and what does the aggregate pattern suggest about the IRA’s actual pricing architecture versus its intended one? Those are questions that MedPricer’s infrastructure is uniquely positioned to help answer.
